In the field of advanced prostate cancer, a number of therapeutic agents are now available. The sequence of administration of medications with distinct mechanisms of action, toxicities and efficacies, will have a critical role in disease outcomes. The identification of biomarkers predicting response will help to determine the appropriate therapeutic sequence.
